Azimuth Capital Management buys $13.1 Million stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Azimuth Capital Management scooped up 4,053 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 243,702 shares of Merck & Co. which is valued at $13.1 Million.Merck & Co. makes up approximately 1.26% of Azimuth Capital Management’s portfolio.

Other Hedge Funds, Including , Holderness Investments Co boosted its stake in MRK in the latest quarter, The investment management firm added 2,152 additional shares and now holds a total of 21,192 shares of Merck & Co. which is valued at $1.1 Million. Merck & Co. makes up approx 1.10% of Holderness Investments Co’s portfolio.Kahn Brothers Group Inc De reduced its stake in MRK by selling 25,508 shares or 2.52% in the most recent quarter. The Hedge Fund company now holds 985,419 shares of MRK which is valued at $53.1 Million. Merck & Co. makes up approx 10.20% of Kahn Brothers Group Inc De’s portfolio.Sonora Investment Management reduced its stake in MRK by selling 55 shares or 1.88% in the most recent quarter. The Hedge Fund company now holds 2,864 shares of MRK which is valued at $154,312. Merck & Co. makes up approx 0.08% of Sonora Investment Management’s portfolio.State Of New Jersey Common Pension Fund D reduced its stake in MRK by selling 900,000 shares or 18.07% in the most recent quarter. The Hedge Fund company now holds 4,080,000 shares of MRK which is valued at $223.7 Million. Merck & Co. makes up approx 1.00% of State Of New Jersey Common Pension Fund D’s portfolio.Rothschild Investment Corp Il reduced its stake in MRK by selling 1,837 shares or 2.83% in the most recent quarter. The Hedge Fund company now holds 62,999 shares of MRK which is valued at $3.5 Million. Merck & Co. makes up approx 0.45% of Rothschild Investment Corp Il’s portfolio.

Merck & Co. opened for trading at $53.77 and hit $54.77 on the upside on Monday, eventually ending the session at $54.65, with a gain of 1.43% or 0.77 points. The heightened volatility saw the trading volume jump to 66,49,085 shares. Company has a market cap of $151,273 M.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.